NEWS New study on inheritance and fetal growth by umsjon | Jul 19, 2021 | NEWS Scientists from deCODE genetics have mapped 243 sequence variants affecting fetal growth, separating maternal genome and fetal genome. It sheds light on the relationships between hypertension, diabetes and fetal growth read more New biomarker for osteoarthritis by umsjon | Jun 22, 2021 | NEWS Scientists at deCODE genetics have found a new biomarker for osteoarthritis, that outperforms previously reported biomarkers and is an independent predictor of disease. read more Predicting the probability of death by umsjon | Jun 18, 2021 | NEWS Scientists from deCODE genetics have developed a predictor based on protein measurements in blood samples that predicts the time to all-cause death better than traditional risk factors. read more Rounding off the human genome by umsjon | May 10, 2021 | NEWS In a study published today, scientists at deCODE Genetics demonstrate for the first time how long-read DNA sequencing can be applied at population scale to unravel large structural variants that associate with human disease and other traits. read more Monozygous but not identical by umsjon | Jan 7, 2021 | NEWS By sequencing the germline genomes of twins and comparing them to those of close relatives, scientists at deCODE genetics found mutations that are present in just one of the monozygotic twins and traced them back to the first days after conception. read more Titers of antibodies against SARS-CoV2 do not decline within four months by umsjon | Sep 1, 2020 | NEWS Scientists at deCODE genetics and their collaborators, have published a study in The New England Journal of Medicine, that shows that antiviral antibodies against SARS-CoV2 do not decline within four months of diagnosis. read more Dietary cholesterol and phytosterols contribute directly to heart disease by umsjon | Aug 7, 2020 | NEWS Genetic variability in cholesterol and phytosterol absorption affects cardiovascular disease risk read more Loss of function variant in FLT3 strongly increases the risk of autoimmune thyroid disease and other autoimmune diseases by umsjon | Jun 24, 2020 | NEWS The combination of genomics, transcriptomics and proteomics sheds light on autoimmune thyroid disease, other autoimmune diseases and AML read more Icelandic Genomes Elucidate Neanderthal Heritage of Europeans by umsjon | Apr 22, 2020 | NEWS Archaic genetic fragments comprising nearly half the Neanderthal genome are circulating in the European gene pool today. The average European carries more than 500 such archaic fragments, including SNPs linked to prostate cancer risk, iron retention, blood clotting speed, and height read more Iceland Provides a Picture of the Early Spread of COVID-19 in a Population With a Cohesive Public Health Response by umsjon | Apr 15, 2020 | NEWS Study combines the most intensive targeted testing and general screening of any population to date with comprehensive sequencing of the virus from all identified cases, to trace its mutation and spread Results underscore the effectiveness and necessity of aggressive testing, isolation of cases and physical distancing, as well as the urgency of more testing to contain the virus and disease read more Beyond Cholesterol: Landmark deCODE Study Elucidates Role of Lipoprotein(a) as Major Risk Factor for Heart Disease by umsjon | Dec 9, 2019 | NEWS Highly diverse, understudied and not routinely screened for, Lp(a) — an alipoprotein(a) bound to an LDL cholesterol particle — may be the next most important serum risk factor after LDL itself Results provide population-based evidence in support of standardized... read more deCODE in Iceland agrees to sequence half of UK Biobank participants by umsjon | Sep 11, 2019 | NEWS REYKJAVIK, Iceland, 11. September. 2019. deCODE genetics in Iceland has entered into an agreement with a consortium of government, charity, researchers and world leading biopharmaceutical and healthcare companies to undertake whole genome sequencing of UK Biobank... read more Kári Stefánsson elected to National Academy of Science by umsjon | May 3, 2019 | NEWS Kári Stefánsson, the founder and CEO of deCODE Genetics, now a subsidiary of Amgen, has been elected to the National Academy of Science (NAS). Election to the academy is one of the highest honors in the field of science and a recognition reserved for individuals whose careers are distinguished by original and continuing achievements in their areas of research. read more Leaders of Nordic Society of Human Genetics and Precision Medicine by umsjon | Apr 11, 2019 | NEWS Kári Stefánsson CEO of deCODE genetics seeks to unite Nordic researchers in genetic research to support more precise and personalised medical treatment . The Nordic Society of Human Genetics and Precision Medicine (NSHG-PM) has chosen its inaugural leadership.... read more deCODE Publishes the First Full Resolution Genetic Map of the Human Genome by umsjon | Jan 24, 2019 | NEWS A whole genome sequence-based portrait of how the two basic mechanisms generating human diversity work Elucidates how women and men contribute differently to diversity; how the genome promotes and regulates diversity; and the link between the generation of diversity... read more A variant that protects against nasal polyps and chronic rhinosinusitis by umsjon | Jan 18, 2019 | NEWS Scientists at deCODE genetics have found a variant that protects against nasal polyps and chronic rhinosinusitis. The study was published on the 14th of January in the online edition of Nature genetics. Nasal polyps are non-malignant, typically bilateral growths on... read more When Memory Wanes by deCODE genetics | Sep 25, 2018 | NEWS read more The Making of a Human Population Uncovered Through Ancient Icelandic Genomes by deCODE genetics | May 31, 2018 | NEWS In a study published today, scientists at deCODE Genetics report new findings about the founding of the Icelandic population, and its subsequent evolution, based on ancient DNA. The study appears today in the online edition of Science. Iceland was settled around 1100... read more The Nature of Nurture – deCODE Study Highlights the Important Role of Genes in Nurture by deCODE genetics | Jan 25, 2018 | NEWS In a study published tomorrow, researchers at deCODE genetics demonstrate that parental genes, both those that are transmitted to the child and those not transmitted, can affect the child’s fate through their impact on the parents and the kind... read more deCODE Study Reveals an Ancient Achilles Heel in the Human Genome by deCODE genetics | Sep 20, 2017 | NEWS The generation of new mutations is a key driver of evolution but also of susceptibility to rare diseases Fathers pass on four times as many new mutations as mothers do, but the maternal contribution is particularly strong in 10% of the genome that is prone to... read more The American Society of Human Genetics honors Kári Stefánsson with William Allan Award by deCODE genetics | Jul 12, 2017 | NEWS The American Society of Human Genetics (ASHG) has named Kári Stefánsson, MD, founder of deCODE genetics, the 2017 recipient of the annual William Allan Award. The William Allan Award is the top prize given by the ASHG and recognises a scientist for substantial and... read more deCODE study shows that variants in the sequence of the genome that contribute to educational attainment are under negative selection by deCODE genetics | Jan 17, 2017 | NEWS In a study published today, scientists at deCODE genetics use genomic and genealogical data from across the population of Iceland over many decades to show that people who carry sequence variations linked to higher levels of education have fewer children than average.... read more deCODE genetics study shows that human genetic diversity is the outcome of a battle between the sexes by deCODE genetics | Sep 19, 2016 | NEWS REYKJAVIK, Iceland, 19 September 2016 – In a new study, researchers at deCODE genetics have used their unique population data resources to shed new light on the processes which continuously shape the diversity of the human genome. In previous studies, they... read more Landmark deCODE genetics Study Points to a New Mechanism that Affects Cholesterol Levels and The Risk of Heart Disease by deCODE genetics | May 18, 2016 | NEWS Analyzes genome, cholesterol and heart disease data from 700,000 people in seven countries Individuals with a rare twelve-letter deletion from a gene on chromosome 17 have significantly reduced non-HDL cholesterol levels and a 35% lower than average risk of heart... read more Beyond LDL: deCODE Population-wide Study in Iceland Refines Understanding of Link Between Cholesterol and Heart Disease by deCODE genetics | May 4, 2016 | NEWS Analyzes whole genome and detailed clinical data from nearly 300,000 Icelanders Finds several novel variations in the sequence of the human genome modulating cholesterol levels Five variants are also causally linked to increased risk of coronary artery disease Shows... read more The Genetics of Thinking Differently: deCODE Uncovers Shared Roots of Psychosis and Creativity by deCODE genetics | Jun 8, 2015 | NEWS A multinational study of data from 130,000 people shows that inherited risk factors for schizophrenia and bipolar disorder also predict participation in the arts and creative professions REYKJAVIK, Iceland, 8 June 2015 – A study led by scientists at deCODE genetics... read more The Genomic Portrait of a Nation by deCODE genetics | Mar 25, 2015 | NEWS The largest studies of whole-genome data ever published reveal the power of the sequencing revolution for understanding the roots of disease, diversity and evolution: The most comprehensive population-wide tally to date of sequence variation A nationwide collection of... read more deCODE genetics Uncovers Impact of Mutations in The Human Genome on Cognitive Ability by deCODE genetics | Dec 18, 2013 | NEWS REYKJAVIK, Iceland, Dec. 18, 2013 - deCODE genetics, a global leader in analyzing and understanding the human genome, reported today in the journal Nature that mutations associated with an increased risk of schizophrenia and autism also affect cognition in individuals... read more A Mutation Discovered in Iceland that Increases Risks of Osteoporosis and Certain Cancers by deCODE genetics | May 5, 2013 | NEWS Nature Published Study Illustrates Value of Big Data Research Methods deCODE genetics (an Amgen subsidiary) and Illumina, global leaders in analyzing and understanding the human genome, together with scientists from the National Hospital of Iceland and the University... read more Amgen to Acquire deCODE Genetics, a Global Leader in Human Genetics by deCODE genetics | Dec 12, 2012 | NEWS deCODE Genetics Will Provide Amgen With an Industry-Leading Ability to Identify and Validate Disease Targets in Human Populations THOUSAND OAKS, Calif. and REYKJAVIK, Iceland, Dec. 10, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and deCODE Genetics today announced that... read more deCODE Genetics, Multinational Research Team Find Gene Variant Conferring High Risk for Common, Late-Onset Form of Alzheimer’s Disease by deCODE genetics | Nov 14, 2012 | NEWS Findings Published in New England Journal of Medicine Provide New Focus for Drug Discovery Study Demonstrates Power of “Big Data” Research REYKJAVIK, Iceland - deCODE Genetics and Illumina, global leaders in analyzing and understanding the human genome, together with... read more deCODE Genetics Study Finds Father’s Age—Not Mother’s Critical to New Mutations Passed to Offspring by deCODE genetics | Aug 23, 2012 | NEWS Nature Published Study Signals Rise in Autism Spectrum Disorder May Be Partially Tied to Increasing Age of Fathers at Time When Children are Conceived deCODE Genetics, a global leader in analyzing and understanding the human genome, in collaboration with Illumina, a... read more deCODE Genetics Discovers Mutation Conferring Protection Against Alzheimer’s Disease and Cognitive Decline in Elderly by deCODE genetics | Jul 11, 2012 | NEWS Study Indicates Link Between Age-Related Cognitive Decline and Alzheimer’s Disease Results Support Drug Development of BACE1 Inhibitors for Alzheimer’s Disease Reykjavik, ICELAND, July 11, 2012 – deCODE Genetics, a global leader in analyzing and understanding the... read more deCODE Genetics, in Collaboration with Academic Colleagues, Discovers Three Variants in the Sequence of the Human Genome that Affect the Risk of Thyroid Cancer by deCODE genetics | Jan 22, 2012 | NEWS Reykjavik, ICELAND, 22 January 2012 – Scientists at deCODE Genetics and academic collaborators from Iceland, the USA, The Netherlands and Spain today report the discovery of variants in the human genome that associate with levels of thyroid stimulating hormone and... read more deCODE Announces Agreement with Pfizer to Search for Variants in the Human Genome that Confer Risk of Systemic Lupus Erythematosis by deCODE genetics | Oct 12, 2011 | NEWS Reykjavik, ICELAND, 12 October 2011 – deCODE genetics today announced that it has entered into a research collaboration with Pfizer Inc., the objective of which is to discover sequence variants associated with specific clinical phenotypes related to Systemic Lupus... read more deCODE Genetics, in Collaboration with Academic Colleagues and Illumina, Discovers Two Rare Variants that Affect the Risk of Gout and Serum Uric Acid Levels by deCODE genetics | Oct 9, 2011 | NEWS Reykjavik, ICELAND, 9 October 2011 – Scientists at deCODE Genetics and academic collaborators from Iceland, Norway, Denmark, the Netherlands and the USA today report the discovery of low frequency variants in the human genome that associate with risk of gout, a common... read more deCODE Genetics, in Collaboration with Academic Colleagues and Illumina, Discovers Mutations Conferring High Risk of Ovarian Cancer by deCODE genetics | Oct 2, 2011 | NEWS Scientists at deCODE Genetics and academic collaborators from Iceland, The Netherlands, Spain and Finland today report the discovery of variants in the human genome that associate with increased risk of invasive ovarian cancer, one of the deadliest forms of cancer in... read more deCODE genetics, Together with Academic Collaborators and Illumina, Discovers Genetic Risk Factor for Skin, Prostate and Brain Cancers by deCODE genetics | Sep 25, 2011 | NEWS Reykjavik, ICELAND, 25 September 2011 – Scientists at deCODE Genetics and academic collaborators from Iceland, The Netherlands, Spain, Denmark, Germany, Sweden, the USA, the UK and Romania today report the discovery of a variant in the sequence of the human genome... read more deCODE Discovers Genetic Risk Factor for Sick Sinus Syndrome by deCODE genetics | Mar 6, 2011 | NEWS Reykjavik, ICELAND, 6 March 2011 – Scientists at deCODE genetics and academic colleagues from Iceland, The Netherlands, Denmark, USA and Illumina, Inc., today report the discovery of single-letter variants (SNPs) in the sequence of the human genome associated with... read more deCODE discovers genetic markers that improve the power of PSA testing for detecting Prostate Cancer by deCODE genetics | Dec 15, 2010 | NEWS Analysis of four SNPs, in tandem with genetic risk factors detected by the deCODE ProstateCancer™ test, yields substantial improvement in efficacy of PSA screening Reykjavik, ICELAND, 15 December 2010 – Scientists from deCODE genetics and academic colleagues from... read more The New deCODE Map of the Human Genome by deCODE genetics | Oct 27, 2010 | NEWS The most detailed template yet of the different ways in which women and men, individuals and populations, are driving one of the main motors of evolution. Reykjavik, ICELAND, 27 October 2010 – Scientists from deCODE genetics today publish in Nature the highest... read more Not only Size Matters: Genetic Megastudies Draw out Distinctions between Obesity and Waist-Hip Ratio by deCODE genetics | Oct 11, 2010 | NEWS Independent of obesity itself, WHR is a key indicator of risk of diabetes, heart disease and mortality, and appears to be regulated differently in women and men Reykjavik, ICELAND, 11 October 2010 – In two of the largest metastudies of their kind to date, scientists... read more deCODE Validates Genetic Risk Factors for Osteoporosis in Chinese and Korean Populations by deCODE genetics | Oct 7, 2010 | NEWS Study is part of broad effort to make genetic risk factors discovered in one part of the world relevant to people of other continental ancestries Reykjavik, ICELAND, 7 October 2010 – In a study published today, scientists at deCODE genetics and academic colleagues in... read more deCODE Discovers Major Genetic Risk Factor for the most Common Form of Glaucoma by deCODE genetics | Sep 13, 2010 | NEWS SNP on chromosome 7 is rare among Chinese but confers five-fold increase in risk; underscores importance of analyzing risk factors across continental ancestries Reykjavik, ICELAND, 13 September 2010 – Scientists at deCODE genetics and academic colleagues from Iceland,... read more deCODE Shows How Genetic Risk of Kidney Disease Frames Response to Environmental Risk over Time by deCODE genetics | Jul 29, 2010 | NEWS A SNP on chromosome 16 appears to confer risk by affecting how the renal system adapts to the impact of aging and the onset of other common diseases Reykjavik, ICELAND, 29 July 2010 – Scientists at deCODE genetics and colleagues at Radboud University in the... read more Found in Translation: deCODE Maps Asian Breast Cancer Risk Factor in Women of African and European Descent by deCODE genetics | Jul 23, 2010 | NEWS Reykjavik, ICELAND, 23 July 2010 – In a paper published today in PLoS Genetics, a deCODE-led team demonstrates an effective approach for making genetic risk factors discovered on one continent fully relevant to people of various continental ancestries. The strategy,... read more ARUP Laboratories Ink Partnership To Offer deCODE ProstateCancer™ Test by deCODE genetics | Jul 20, 2010 | NEWS U.S. laboratories and physicians will be able to use their ARUP accounts to order deCODE’s test for assessing risk of prostate cancer Reykjavik, ICELAND, and Salt Lake City, UTAH,– July 20, 2010 – deCODE genetics and ARUP Laboratories today announced a partnership... read more deCODE Discovers Genetic Risk Factor Linking Susceptibility to Four Major Vascular Diseases by deCODE genetics | Jul 11, 2010 | NEWS Points to novel pathway for drug discovery, will be incorporated into tests to improve screening and early detection of abdominal aortic aneurysm, heart attack and PAD Reykjavik, ICELAND, 11 July 2010 – Scientists at deCODE genetics and academic colleagues from the... read more Smoking: New Genetic Factors Behind Nicotine Dependence and Lung Cancer by deCODE genetics | Apr 25, 2010 | NEWS Reykjavik, ICELAND, April 25, 2010 – Cigarette smoking is a major cause of illness and death worldwide. But it is a complex behavior, and how much people smoke, how hard they find it to quit, and the impact of long-term smoking on health varies greatly among... read more deCODE and Radboud Discovery in Bladder Cancer May Link Disease Risk and Somatic Mutations in Tumors by deCODE genetics | Mar 29, 2010 | NEWS Reykjavik, ICELAND and Nijmegen, THE NETHERLANDS, March 29, 2010 – Sequence variants associated with cancer have to date fallen into two distinct categories. Variants in the ordinary, or “germline,” sequence of the genome that is passed between generations were linked... read more Announcing the New deCODE by deCODE genetics | Jan 21, 2010 | NEWS Reykjavik, ICELAND, January 21, 2010 – deCODE genetics ehf today emerged as a newly financed, private company focused on advancing the science of human genetics and its application to products and services that improve human health. The new company will be building on... read more Novel SNPs modulate ECG measurements including heart rate, two are also risk factors for atrial fibrillation and will be integrated into deCODE AF™ test by deCODE genetics | Jan 10, 2010 | NEWS Reykjavik, ICELAND, January 10, 2010 – Scientists at deCODE genetics today report the discovery of seven novel and common single-letter variations in the sequence of the human genome (SNPs) that are involved in modulating the electrical impulses that govern the... read more deCODE Discovers A Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin by deCODE genetics | Dec 16, 2009 | NEWS A single SNP that confers increased risk if inherited from the father, but is protective if inherited from the mother Reykjavik, ICELAND, December 16, 2009 – Scientists at deCODE genetics, Inc. (Nasdaq:DCGN) publish in the journal Nature the discovery of a version of... read more Multinational Metastudy Identifies New Genetic Variations Contributing to Risk of Osteoporosis by deCODE genetics | Oct 4, 2009 | NEWS Reykjavik, ICELAND, October 4, 2009 – Scientists from deCODE genetics (Nasdaq:DCGN) and academic colleagues from seven countries today report the discovery of several novel, common single-letter variations in the sequence of the human genome (SNPs) contributing to... read more deCODE Discovers Four New Risk Factors for Prostate Cancer by deCODE genetics | Sep 20, 2009 | NEWS Findings further increase power of DNA-based testing to identify men at substantially increased risk, and will be integrated into the deCODE ProstateCancer™ test Reykjavik, ICELAND, September 20, 2009 – deCODE genetics (Nasdaq:DCGN) today announced that a team of its... read more deCODE Discovers Second Common Genetic Risk Factor for Atrial Fibrillation and Stroke by deCODE genetics | Jul 13, 2009 | NEWS Will be integrated into deCODE AF™ DNA-based risk assessment test, and into the deCODEme™ and deCODEme Cardio™ scans Reykjavik, ICELAND, July 13, 2009 – Scientists at deCODE genetics (Nasdaq:DCGN) and colleagues from Europe and the United States today report the... read more It’s Not Just the Sun: deCODE Discovers Sequence Variants Affecting Susceptibility to Skin Cancer by deCODE genetics | Jul 6, 2009 | NEWS New risk factors for basal cell carcinoma that are independent of fair pigmentation; findings to be integrated into deCODEme™ and deCODEme Cancer™ scans Reykjavik, ICELAND, July 6, 2009 – Scientists at deCODE genetics (Nasdaq:DCGN) and academic colleagues from Europe... read more Findings expand knowledge of the biology of the disease and provide potential new drug targets by deCODE genetics | Jul 1, 2009 | NEWS Reykjavik, ICELAND, July 1, 2009 – The largest study of the genetics of schizophrenia ever undertaken has revealed several new common single-letter variants in the sequence of the human genome (SNPs) linked to risk of the disease. The study, by a multinational... read more deCODE Discovers a Gene Linked to Risk of Kidney Stones and Osteoporosis by deCODE genetics | Jun 29, 2009 | NEWS Findings offer promising target for drugs to better regulate calcium metabolism, are integrated into deCODEme™ Reykjavik, ICELAND, June 29, 2009 – A discovery by scientists at deCODE genetics (Nasdaq:DCGN) and academic colleagues from Iceland, the Netherlands and... read more deCODE Genotyping Laboratory Receives College of American Pathologists Accreditation by deCODE genetics | May 20, 2009 | NEWS Underscores quality of deCODE’s laboratory and tests, fulfilling key federal and state certification requirements and broadening marketing channels Reykjavik, ICELAND, May 20, 2009 – deCODE genetics (Nasdaq:DCGN) today announced that its CLIA-registered DNA isolation... read more deCODE Study Shows Complex Interplay of the Human Biological Clock with Height, Weight and Disease by deCODE genetics | May 17, 2009 | NEWS Reykjavik, ICELAND, May 17, 2009 – In a paper published today in the online edition of Nature Genetics, scientists from deCODE genetics (Nasdaq:DCGN) and academic colleagues from Iceland, Denmark and the Netherlands present the discovery of single letter variations in... read more deCODE and Celera Partner to Expand Use of deCODE Risk Markers for Heart Attack, Stroke and Diabetes by deCODE genetics | Apr 23, 2009 | NEWS Reykjavik, ICELAND, and Alameda, CA - April 23, 2009 – deCODE genetics (NASDAQ:DCGN) and Celera Corporation (NASDAQ:CRA) today announced the signing of agreements under which deCODE has granted Celera non-exclusive worldwide licenses to deCODE’s genetic markers for... read more deCODE Receives California Clinical Laboratory License by deCODE genetics | Feb 19, 2009 | NEWS Californians can now enjoy the benefits of deCODE’s market-leading DNA-based disease risk assessment tests and pioneering deCODEme™ genome scans Reykjavik, ICELAND, February 19, 2009 – deCODE genetics (Nasdaq:DCGN) today announced that it has received a clinical... read more Multinational deCODE Study Identifies New Link Between Inflammation and Heart Attack by deCODE genetics | Feb 9, 2009 | NEWS Genetic variants influencing white blood cell counts are linked to increased risk of heart attack and asthma; variants are being integrated into deCODEme™ Reykjavik, ICELAND, February 9, 2009 – In a paper published today, scientists at deCODE genetics (Nasdaq:DCGN)... read more deCODE Breakthrough in Thyroid Cancer May Enable More Targeted Risk Asessment and Earlier Intervention by deCODE genetics | Feb 6, 2009 | NEWS Reykjavik, ICELAND, February 6, 2009 – Scientists at deCODE genetics (Nasdaq:DCGN) today present the discovery of two single letter variations in the sequence of the human genome (SNPs) conferring substantial increased risk of thyroid cancer. The two SNPs, located on... read more deCODEme™ Takes on Heart Disease in February by deCODE genetics | Feb 3, 2009 | NEWS deCODEme Cardio™ scan offered at $100 during American heart Month; CEO Kari Stefansson to appear on The Martha Stewart Show this Thursday, February 5th Reykjavik, ICELAND, February 3, 2009 – To mark American Heart Month, deCODE genetics (Nasdaq:DCGN) today announced... read more deCODE Discovers First Genetic Variant Conferring Increased Risk of Essential Tremor by deCODE genetics | Feb 2, 2009 | NEWS Finding points directly to a promising target for drug development and has already been integrated into the deCODEme™ genome analysis service Reykjavik, ICELAND, February 2, 2009 – Scientists from deCODE genetics (Nasdaq:DCGN) today report the discovery of the first... read more A Milestone in Cancer Genetics: deCODE Discovers First Common Genetic Variants Affecting the Risk of Many Types of Cancer by deCODE genetics | Jan 19, 2009 | NEWS Findings point to common mechanisms of susceptibility to cancers of the lung, bladder, prostate, cervix and skin; findings to be integrated into deCODEme™, the new deCODEme Cancer Scan™, and deCODE’s DNA-based risk diagnostic tests Reykjavik, ICELAND, January 19, 2009... read more Introducing deCODEme Cardio™ and deCODEme Cancer™ by deCODE genetics | Jan 18, 2009 | NEWS Focused Genetic Scans Offer Individuals a New Way to Better Understand their Risk of Cardiovascular Disease and Common Cancers Reykjavik, ICELAND, January 18, 2009 – Through deCODEme™, the world’s first first retail genome analysis service, deCODE genetics... read more Stories from Our Foremothers: deCODE Publishes an Unparalleled Genetic Snapshot of Iceland 1000 Years Ago by deCODE genetics | Jan 16, 2009 | NEWS Reykjavik, ICELAND, January 16, 2009 – In a paper published today scientists at deCODE genetics (Nasdaq:DCGN) present the results of the largest study of ancient DNA from a single population ever undertaken. Analyzing mitochondrial DNA, which is passed from mother to... read more deCODE Discovers Common Genetic Variations Contributing to Low Bone Mineral Density and Risk of Osteoporosis by deCODE genetics | Dec 15, 2008 | NEWS Findings point to potential therapeutic pathways and provide widening basis for the development of a risk assessment test Reykjavik, ICELAND, December 15, 2008 – Scientists from deCODE genetics (Nasdaq:DCGN) and colleagues from Australia and Denmark today report the... read more Major deCODE-led Study Underscores Role of the Brain in Obesity by deCODE genetics | Dec 14, 2008 | NEWS New genetic variants linked to obesity are being integrated into the deCODEme™ personal genome analysis service Reykjavik, ICELAND, December 14, 2008 – In one of the largest studies of its kind, a multinational team led by scientists from deCODE genetics (Nasdaq:DCGN)... read more deCODE to Integrate New Genetic Risk Factor for Type 2 Diabetes into its deCODEme Personal Genome Scan Service by deCODE genetics | Dec 8, 2008 | NEWS Reykjavik, ICELAND, December 8, 2008 – deCODE genetics (Nasdaq:DCGN) today announced the discovery by an international consortium of scientists from deCODE and major European and US academic institutions of a single letter variation in the human genome (SNP) that is... read more Major Independent Study Underscores Utility of deCODE MI™ for Better Predicting Risk of Heart Attack, Informing Statin Therapy by deCODE genetics | Nov 11, 2008 | NEWS Reykjavik, ICELAND, November 11, 2008 – In a presentation today at the American Heart Association Scientific Sessions 2008, clinicians and researchers from Baylor College of Medicine have presented data from the Atherosclerosis Risk in Communities (ARIC) study,... read more deCODE Requests Hearing With Nasdaq Following Receipt of Staff Determination Letter by deCODE genetics | Nov 4, 2008 | NEWS Reykjavik, ICELAND, November 4, 2008 – deCODE genetics (Nasdaq:DCGN) today announced today that it has requested a hearing before a Nasdaq Listing Qualifications Panel to present a plan for regaining compliance with Nasdaq Marketplace Rule 4450(b)(1)(A), which... read more deCODE genetics Announces Webcast of Conference Call to Discuss Third Quarter 2008 Financial Results by deCODE genetics | Oct 28, 2008 | NEWS Reykjavik, ICELAND, October 28, 2008 - deCODE genetics, Inc. (Nasdaq:DCGN) today announced that it will report its third quarter 2008 financial results in a press release to be issued on Thursday, November 6, after the close of the market in New York. The company will... read more deCODE Discovery Sheds Light on Risk of the Most Common Form of Skin Cancer by deCODE genetics | Oct 13, 2008 | NEWS Latest discoveries add to understanding of individual risk of basal cell carcinoma, and are integrated into the deCODEme™ personal genome analysis scan Reykjavik, ICELAND, October 13, 2008 – Scientists at deCODE genetics (Nasdaq:DCGN) today report the discovery of... read more deCODE Launches deCODE BreastCancer™, a Genetic Test to Screen for Risk of the Most Common Forms of Breast Cancer by deCODE genetics | Oct 8, 2008 | NEWS Enables women to understand whether they may benefit from more intensive screening, monitoring or preventive drug therapy Reykjavik, ICELAND, October 8, 2008 – deCODE genetics (Nasdaq:DCGN) today announced the launch of deCODE BreastCancer™, a new tool for assessing... read more deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer’s and Other Cognitive Disorders by deCODE genetics | Oct 3, 2008 | NEWS Reykjavik, ICELAND, October 3, 2008 – deCODE genetics (Nasdaq:DCGN) today announced the filing of an investigational new drug (IND) application for DG071, the company’s novel small-molecule modulator of phosphodiesterase 4 (PDE4), with the US Food and Drug... read more deCODE and Radboud University Discover Common Variants in the Human Genome Conferring Risk of Bladder Cancer by deCODE genetics | Sep 14, 2008 | NEWS Detection may be used to complement and target screening for the disease; variants will be integrated into the deCODEme™ personal genome scan. Reykjavik, ICELAND, September 14, 2008 – Scientists at deCODE genetics (Nasdaq:DCGN) and colleagues at Radboud University... read more New deCODE Analytical Tool Multiplies Power to Discover Rare Genetic Risk Factors for Common Diseases by deCODE genetics | Aug 17, 2008 | NEWS A cost-effective method to enable deCODE to extend its leadership in gene discovery to the next challenge in developing market-leading DNA-based diagnostics August 17, 2008 – deCODE has developed a novel analytical method to increase severalfold the amount of... read more deCODE and SGENE Consortium Discover Deletions in the Human Genome Linked to Risk of Schizophrenia by deCODE genetics | Jul 30, 2008 | NEWS Findings may provide the foundation for a test to complement standard clinical diagnosis, potentially enabling earlier intervention and treatment Reykjavik, ICELAND, July 30, 2008 – In a major paper published today in the online edition of the journal Nature,... read more DG041 Blocks Platelet Aggregation Through a Novel Mechanism and does not Increase Bleeding Time When Given Alone or With Plavix™ or Aspirin by deCODE genetics | Jun 30, 2008 | NEWS DG041 Blocks Platelet Aggregation Through a Novel Mechanism and does not Increase Bleeding Time When Given Alone or with Plavix™ or Aspirin Reykjavik, ICELAND, June 30, 2008 – deCODE genetics (Nasdaq:DCGN) today announced positive topline results from its latest... read more Marketing of Diagnostics and deCODEme™, Recent Progress in Drug Development to be Highlighted at deCODE R&D Event by deCODE genetics | Jun 30, 2008 | NEWS Reykjavik, ICELAND, June 30, 2008 ― At its annual R&D event being held today in New York, deCODE genetics (Nasdaq:DCGN) will provide an update on progress in all aspects of its business, including the commercial potential and marketing rollout for its growing range of... read more deCODE Discovers Novel Genetic Link Between Pigmentation Traits and Risk of Skin Cancer by deCODE genetics | May 18, 2008 | NEWS Discoveries help to detail how some fair coloring traits contribute to risk of skin cancer; findings will be integrated into the deCODEme™ service Reykjavik, ICELAND, May 18, 2008 – In two papers published today, deCODE scientists and academic colleagues from Europe... read more deCODE Discovers Genetic Variants Influencing Bone Mineral Density by deCODE genetics | Apr 29, 2008 | NEWS Findings underscore deCODE’s ability to identify genetic risk factors in the most complex traits, and have been integrated into the deCODEme™ service Reykjavik, ICELAND, April 29, 2008 – In a paper published today in the New England Journal of Medicine, a team of... read more deCODE Lauds Federal Legislation to Ban Discrimination on the Basis of Genetic Information by deCODE genetics | Apr 25, 2008 | NEWS Reykjavik, ICELAND, April 25, 2008 – deCODE genetics (Nasdaq:DCGN) today expressed its enthusiastic support for the Genetic Information Non-discrimination Act (GINA), a bill that, many years in the making, is now moving swiftly through Congress and is expected to be... read more deCODE Identifies Novel Regions of the Genome that Affect Normal Adult Height by deCODE genetics | Apr 6, 2008 | NEWS April 6, 2008 – Scientists at deCODE genetics have identified 27 regions in the human genome that affect adult height. These variants, which are published today in the online edition of Nature Genetics, together explain an estimated 4% percent of the normal population... read more A Smoking Gene: deCODE Shows How a Single Variant in the Sequence of the Genome Confers Nicotine Dependence and Risk of Lung Cancer and Other Disease by deCODE genetics | Apr 2, 2008 | NEWS Reykjavik, ICELAND, April 02, 2008 – Cigarette smoking is a major public health problem that contributes to millions of deaths around the world each year. While the health risks of smoking are well known, relatively little is known about why some people are... read more deCODE Obesity Study Sheds Light on how Genetics Affect Risk and Onset of Common Diseases by deCODE genetics | Mar 16, 2008 | NEWS Reykjavik, ICELAND, March 16, 2008 – In a paper published online today in the journal Nature, a team of deCODE scientists detail a major mechanism through which genetic factors contribute to major public health problems. In its work on the inherited components of... read more deCODE launches a DNA-based test for assessing risk of prostate cancer on the back of the discovery of new prostate cancer genes by deCODE genetics | Feb 10, 2008 | NEWS New risk variants published today will also be folded into deCODEme™ Reykjavik, ICELAND, February 10, 2008 - deCODE genetics (Nasdaq: DCGN) today announced the launch of deCODE PrCa™, a reference laboratory test for common, single-letter variations in the human genome... read more deCODE Links Closer Kinship with Reproductive Success by deCODE genetics | Feb 7, 2008 | NEWS Phenomenon could have long-term impact on population growth in urbanizing societies Reykjavik, February 7, 2008 – In a paper published today deCODE scientists establish a substantial and consistent positive correlation between the kinship of couples and the number of... read more deCODE Discovers Gene Variants that May Help to Distribute the Work of Evolution between Men and Women by deCODE genetics | Jan 31, 2008 | NEWS Reykjavik, ICELAND, January 31, 2008 – Scientists from deCODE genetics (Nasdaq:DCGN) today report the discovery of two common, single-letter variants in the sequence of the human genome (SNPs) that regulate one of the principle motors of evolution. Versions of the two... read more Positive Results from Phase IIa Study Pave Way for Phase IIb Trial of DG051 for the Prevention of Heart Attack by deCODE genetics | Jan 9, 2008 | NEWS Reykjavik, ICELAND, January 9, 2008 – deCODE genetics (Nasdaq:DCGN) today announced positive topline results from its Phase IIa clinical trial for DG051, the company’s leukotriene A4 hydrolase inhibitor being developed for the prevention of heart attack. With these... read more Not only lipids and inflammation: Insight into a new cause of heart attack and other vascular disease by deCODE genetics | Jan 6, 2008 | NEWS Reykjavik, January 6, 2008 – deCODE scientists today report that the genetic variant on chromosome 9p21 that the company has linked to increased risk of heart attack is also associated with up to 70% increase in risk of abdominal aortic aneurysm (AAA) and intracranial... read more deCODE Announces Availability of deCODEme™ Subscription Gift Certificates ™ by deCODE genetics | Dec 19, 2007 | NEWS Give the holiday gift that can unlock the genome Reykjavik, ICELAND, Dec. 19, 2007 – deCODE genetics (Nasdaq:DCGN) today announced the availability of deCODEme™ gift certificates that allow individuals to give the gift that enables friends and family to get a detailed... read more deCODE Launches deCODEme™ by deCODE genetics | Nov 16, 2007 | NEWS The company that has led in the discovery of genes that confer risk of common diseases is empowering individuals to explore their own genome Reykjavik, ICELAND, Nov. 16, 2007 – deCODE genetics (Nasdaq:DCGN) today announced the launch of deCODEme™, a pioneering service... read more deCODE genetics Showcases DNA-based Diagnostics at American Heart Association Annual Meeting by deCODE genetics | Nov 2, 2007 | NEWS Tests Detect Major Common Genetic Risk Factors for Heart Attack and Stroke Orlando, Florida, November 4-7, 2007 - At this year's Scientific Sessions of the American Heart Association, deCODE genetics (Nasdaq:DCGN) is presenting its newly launched DNA-based risk... read more deCODE Discovers Genetic Variants Influencing Skin, Eye and Hair Color by deCODE genetics | Oct 21, 2007 | NEWS Scientists at deCODE genetics and colleagues in Iceland and Holland today report the discovery of variations in the human genome that influence pigmentation of hair, eyes and skin. By studying more than 300,000 SNPs (single-letter variants in the human genome) across... read more deCODE Launches deCODE MI™ – A Test for a Major Genetic Risk Factor for Early-onset Heart Attack by deCODE genetics | Oct 11, 2007 | NEWS deCODE genetics (Nasdaq:DCGN) today announced the launch of deCODE MI™, a reference laboratory test for variations in the genome (called SNPs) that the company has associated with increased risk of myocardial infarction, or heart attack. The SNPs are located on... read more deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack by deCODE genetics | Oct 9, 2007 | NEWS deCODE genetics (Nasdaq:DCGN) today announced that it has begun enrolling patients for its Phase IIa clinical trial for DG051, the company’s leukotriene A4 hydrolase inhibitor being developed for the prevention of heart attack. In Phase I studies completed earlier... read more deCODE Discovers Cause of Major Subtype of Glaucoma by deCODE genetics | Sep 9, 2007 | NEWS In a paper published today in the journal Science, scientists from deCODE genetics (Nasdaq:DCGN) and academic colleagues from the National University Hospital in Reykjavik and Uppsala University in Sweden report the discovery of two common single letter variations... read more deCODE Gene Discovery Points to New Approach for Treating Major Sleep Disorder by deCODE genetics | Jul 18, 2007 | NEWS Reykjavik, Iceland, July 18, 2007 - Scientists at deCODE genetics (Nasdaq:DCGN) in collaboration with colleagues from Emory University today report the discovery of the first variant in the sequence of the human genome ever linked to risk of Restless Legs Syndrome... read more deCODE Discovers Gene Variant that Confers Risk of Prostate Cancer and Protects Against Type 2 Diabetes by deCODE genetics | Jul 1, 2007 | NEWS In a paper published today, a team of scientists from deCODE genetics (Nasdaq:DCGN) and academic colleagues from Europe and the United States report the discovery of two single letter variations (SNPs) on chromosome 17 associated with increased risk of prostate... read more deCODE Discovers a Variation in the Sequence of the Genome Conferring Risk of Atrial Fibrillation Launches deCODE AF™, A Test for the Risk Variant Aimed at the Prevention of Stroke by deCODE genetics | Jul 1, 2007 | NEWS A paper published today in the journal Nature describes the discovery by scientists at deCODE genetics (Nasdaq:DCGN), in collaboration with academic colleagues in Iceland, the United States, Sweden and China, of two common single-letter variations in the genome (SNPs)... read more Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R &D Event by deCODE genetics | Jun 25, 2007 | NEWS Recent clinical studies support the development of DG041 as an effective anti-platelet that does not increase bleeding risk deCODE genetics (Nasdaq:DCGN) today announced progress in the development of DG041, the company’s Phase II developmental compound for the... read more deCODE Discovers Common Genetic Variants Linked to Increased Risk of Breast Cancer by deCODE genetics | May 27, 2007 | NEWS In a paper published today, a team of scientists from deCODE genetics (Nasdaq:DCGN) and academic colleagues from Europe and the United States report the discovery of two novel and very common genetic variants linked to susceptibility to breast cancer. The variants are... read more deCODE Identifies Novel Genetic Variant Associated with Increased Risk of Heart Attack by deCODE genetics | May 3, 2007 | NEWS Scientists at deCODE genetics (Nasdaq:DCGN) and academic colleagues from the United States today report the discovery of a common genetic variant that confers increased risk of myocardial infarction (MI), or heart attack. The variant, a SNP (a single-letter variant in... read more deCODE Announces Positive Topline Results for Phase I Study of DG051 for the Prevention of Heart Attack by deCODE genetics | May 1, 2007 | NEWS deCODE genetics (Nasdaq:DCGN) today announced positive top-line results from its Phase I multiple dose clinical trial of DG051, which the company is developing for the prevention of heart attack. In the study, a randomized, double-blind, multi-dose, ascending dose,... read more deCODE Launches deCODE T2™, a Novel DNA-based Test for Assessing Inherited Risk of Type 2 Diabetes by deCODE genetics | Apr 15, 2007 | NEWS deCODE genetics, Inc. (Nasdaq:DCGN) today announced the launch of deCODE T2™, a novel DNA-based reference laboratory test for the first common and well-validated genetic risk factor for type 2 diabetes (T2D). deCODE believes this test may provide an important means to... read more deCODE Discovers Second Major Prostate Cancer Risk Variant on Chromosome 8q24 by deCODE genetics | Apr 1, 2007 | NEWS First publication of genome-wide association study leveraging deCODE’s population approach; Finding to be integrated into deCODE’s DNA-based diagnostics program A team of deCODE scientists, along with academic colleagues from the United States, Iceland, Spain and the... read more deCODE Initiates Phase I Clinical Program for DG051 for the Prevention of Heart Attack by deCODE genetics | Aug 14, 2006 | NEWS deCODE genetics (Nasdaq:DCGN) today announced that it has begun enrolling patients in its Phase I clinical development program for DG051, the company’s follow-on developmental compound for the prevention of heart attack. The ascending-dose, double-blind, randomized,... read more deCODE Submits IND on DG051 for the Prevention of Heart Attack by deCODE genetics | Jun 29, 2006 | NEWS June 29, 2006 deCODE genetics (Nasdaq: DCGN) today announced that it has submitted an investigational new drug application (IND) to the US Food and Drug Administration (FDA) for DG051, the company's follow-on investigational compound for the prevention of heart... read more deCODE Announces Positive Results from Preliminary Phase II Clinical Trial of CEP-1347 in Asthma by deCODE genetics | Jun 24, 2006 | NEWS June 24, 2006 deCODE genetics (Nasdaq:DCGN) today announced positive results from its preliminary Phase II clinical trial (Phase IIa) of Cephalon Inc.’s (Nasdaq: CEPH) CEP-1347 in asthma. Data on patients receiving active drug in the trial were consistent with a... read more deCODE Study Links Gene Variant to Risk of Breast Cancer by deCODE genetics | Jun 20, 2006 | NEWS June 20, 2006 A population-based study by a team of deCODE scientists and colleagues at Iceland’s National University Hospital published today provides a detailed look at the impact of a gene variant on risk of breast cancer. The variant is within a gene called BARD1... read more deCODE Initiates Phase III Trial for DG031 for the Prevention of Heart Attack by deCODE genetics | May 17, 2006 | NEWS May 17, 2006 deCODE genetics (Nasdaq:DCGN) today announced the initiation of patient enrollment in the pivotal Phase III trial for DG031, deCODE’s lead developmental compound for the prevention of heart attack. “This is an important study for deCODE and a small... read more deCODE and Illumina Form Alliance to Develop and Commercialize DNA-based Diagnostics by deCODE genetics | May 15, 2006 | NEWS May 15, 2006 deCODE and Illumina Form Alliance to Develop and Commercialize DNA-based Diagnostics Companies to initiate work on molecular diagnostics for the risk of heart attack, type 2 diabetes and breast cancer Illumina to install large-scale genotyping system and... read more deCODE Discovers Major Genetic Risk Factor for Prostate Cancer by deCODE genetics | May 7, 2006 | NEWS May 7, 2006 Milestone in cancer genetics: a common genetic variant conferring significant risk of a common cancer in the general population Scientists at deCODE genetics (Nasdaq:DCGN) along with academic colleagues in Iceland, the US and Sweden today report the... read more deCODE Announces Special Protocol Assessment Agreement with the FDA for Phase III Clinical Trial of DG031 by deCODE genetics | May 3, 2006 | NEWS May 3, 2006 deCODE genetics (Nasdaq:DCGN) today announced that it has reached an agreement with the US Food and Drug Administration (FDA) on the design of its Phase III clinical trial for DG031, deCODE’s lead developmental compound for the prevention of heart attack.... read more deCODE Successfully Completes Phase I Clinical Program for DG041 for the Treatment of Peripheral Artery Disease by deCODE genetics | Feb 21, 2006 | NEWS February 21, 2006 deCODE genetics (Nasdaq:DCGN) today announced top-line results from Phase I clinical studies of DG041, the company's developmental compound for the treatment of peripheral artery disease (PAD). The company has completed the Phase I studies of DG041... read more deCODE Expands Cancer Program through Acquisition of Icelandic Cancer Research Group by deCODE genetics | Jan 18, 2006 | NEWS January 18, 2006 deCODE genetics (Nasdaq:DCGN) today announced its acquisition of privately-held Icelandic cancer research firm Urdur, Verdandi Skuld (UVS). The acquisition enables deCODE to broaden and enhance its cancer program by applying the company's unique gene... read more deCODE Discovers Major Genetic Risk Factor for Type 2 Diabetes by deCODE genetics | Jan 15, 2006 | NEWS January 15, 2006 In a scientific paper published today a team of scientists from deCODE genetics (Nasdaq:DCGN) and colleagues report the discovery of a variant in a gene on chromosome 10 that represents the most significant genetic risk factor for type 2 diabetes... read more deCODE Describes Genetic Risk Factor for Heart Attack Conferring Particularly High Risk in African Americans by deCODE genetics | Nov 10, 2005 | NEWS November 10, 2005 Major discovery with rapid applicability to the development of new medicine Reykjavik, ICELAND, November 10, 2005 – A paper by a deCODE-led team of scientists published today presents the discovery of a gene variant conferring increased risk of... read more deCODE Launches Phase II Clinical Trial in Asthma by deCODE genetics | May 18, 2005 | NEWS Reykjavik, ICELAND, May 18, 2005 – deCODE genetics (Nasdaq:DCGN) today announced that it has begun dosing of patients in a Phase II clinical trial in asthma. deCODE has isolated a gene which plays an important role in the development of asthma. The gene encodes a... read more deCODE Paper in JAMA Describes Efficacy of DG031 in Controlling Key Indicators of Risk for Heart Attack by deCODE genetics | May 10, 2005 | NEWS Reykjavik, ICELAND, May 10, 2005 – deCODE genetics (Nasdaq:DCGN) today announced the publication of a landmark article by a team of its scientists presenting the results of Phase II clinical studies of DG031, the company’s lead compound being developed for the... read more deCODE Initiates Enrollment in Phase I Clinical Trial of DG041 for atherosclerosis by deCODE genetics | Mar 9, 2005 | NEWS Reykjavik, ICELAND, March 9, 2005 – deCODE genetics (Nasdaq:DCGN) today announced that it has begun enrolling subjects in a Phase I clinical trial for DG041, the company’s developmental compound for the treatment of atherosclerosis of the extremeties, commonly known... read more Discovery of Ancient Genetic Inversion Enables Direct Glimpse of Natural Selection in Action in Humans by deCODE genetics | Jan 16, 2005 | NEWS January 16, 2005 – In a paper published in the online edition of Nature Genetics, deCODE scientists describe the discovery of a large and ancient stretch of inverted sequence on chromosome 17. The characteristics and geographic prevalence of this inversion, analyzed... read more deCODE Submits IND for Novel Anti-atherosclerosis Compound DG041 by deCODE genetics | Jan 13, 2005 | NEWS Reykjavik, ICELAND, January 13, 2005 – deCODE genetics (Nasdaq:DCGN) has submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) for DG041, a novel, first-in-class, orally-administered small molecule for the treatment of... read more Major Population-based Study Points to Inherited Risk for Lung Cancer by deCODE genetics | Dec 22, 2004 | NEWS December 22, 2004 Smoking plays a dominant role in the development of the disease, but genetic factors appear to establish increased susceptibility that goes beyond the nuclear family In a paper published today in the Journal of the American Medical Association... read more deCODE Study Provides Detailed Portrait of Population Structure and its Relevance to Genetics Research by deCODE genetics | Dec 19, 2004 | NEWS December 19, 2004 A major study by deCODE scientists of the geographic distribution of genetic variability in the Icelandic population has been published in the online edition of Nature Genetics. The paper by Agnar Helgason, et al., is entitled “An Icelandic example... read more deCODE to Conduct Phase II Clinical Trial in Asthma by deCODE genetics | Dec 17, 2004 | NEWS Reykjavik, ICELAND, December 17, 2004 – deCODE genetics (Nasdaq: DCGN) today announced the signing of an agreement under which it will conduct a Phase II information-rich clinical trial next year of a third-party compound as part of a drug development program in... read more deCODE Study Details Familial Risk for Cancer by deCODE genetics | Dec 4, 2004 | NEWS December 4, 2004 A deCODE study just published in Public Library of Science (PloS) Medicine provides the most comprehensive analyses to date of the importance of inherited risk factors for the most common forms of cancer. The results indicate that increased risk of... read more deCODE Announces Positive Results from Phase IIa Clinical Trial of DG031 by deCODE genetics | Oct 19, 2004 | NEWS • Study achieves primary endpoints; DG031 shown to be well-tolerated and to significantly reduce levels of leukotriene B4 and myeloperoxidase • First ever clinical trial based upon the isolation of a disease gene in a common disease Reykjavik, ICELAND, October 19,... read more Landmark deCODE Study Links Recombination Rate with Fertility: A Mechanism for Increasing Human Diversity by deCODE genetics | Oct 3, 2004 | NEWS October 3, 2004 October 3, 2004 - In a paper published today in the online edition of Nature Genetics, a deCODE-led team of scientists present the results of a large-scale population study linking recombination rate with maternal age and fertility. In the paper,... read more deCODE Completes Enrollment for Phase IIa Clinical Trial of DG031 by deCODE genetics | Jun 18, 2004 | NEWS Study to conclude in late August; data will be used in the design of an information-rich Phase III study for the prevention of heart attack Reykjavik, ICELAND, June 18, 2004 ― deCODE genetics (Nasdaq:DCGN) today announced the completion of enrollment for its ten-week,... read more deCODE Study Identifies First Gene Linked to Significant Risk of Common Form of Heart Attack by deCODE genetics | Feb 6, 2004 | NEWS February 6, 2004 Gene encoding FLAP also confers risk for stroke; discovery pinpoints common biological mechanism underlying two of the world’s biggest public health challenges In a paper published in the online edition of Nature Genetics, a deCODE-led team of... read more deCODE and The Simons Foundation Launch Major Population-based Study of the Genetics of Autism by deCODE genetics | Jan 7, 2004 | NEWS January 7, 2004 Reykjavik, ICELAND, January 7, 2004 — deCODE genetics (Nasdaq:DCGN) and The Simons Foundation, a New York-based organization supporting advanced research in the basic sciences, today announced the launch of the first ever population-based study of the... read more deCODE Isolates Two Major New Obesity Genes under Alliance with Merck by deCODE genetics | Dec 11, 2003 | NEWS Common forms of these genes confer significant predisposition to obesity Reykjavik, ICELAND, December 11, 2003 — deCODE genetics (Nasdaq:DCGN) today announced that it has isolated two new genes as part of its alliance with Merck & Co, Inc. to develop drugs for the... read more deCODE Licenses Developmental Compound, Expects to Start Enrollment for Phase II Clinical Trial in Myocardial Infarction at the Beginning of Next Year by deCODE genetics | Nov 19, 2003 | NEWS Reykjavik, ICELAND, November 17, 2003 — deCODE genetics (Nasdaq:DCGN) today announced that it has acquired an exclusive worldwide license from Bayer AG to develop and commercialize a small molecule compound. The compound is active against a key target, located within... read more deCODE and Roche Diagnostics Announce Discovery of Significant Genetic Risk Factors for Heart Attack DNA-based diagnostics applying these findings may enable more targeted, individualized prevention strategies by deCODE genetics | Oct 17, 2003 | NEWS Reykjavik, ICELAND, and Basel, SWITZERLAND, October 17, 2003 — deCODE genetics (Nasdaq/Nasdaq Europe:DCGN) and Roche Diagnostics today announced a landmark discovery under their alliance to develop DNA-based diagnostic tests for common diseases. deCODE scientists have... read more deCODE Announces Milestone in its Obesity Alliance with Merck by deCODE genetics | Sep 30, 2003 | NEWS deCODE has discovered a gene with certain variations that predispose to obesity and others that predispose to thinness Reykjavik, ICELAND, September 30, 2003 — deCODE genetics (Nasdaq/Nasdaq Europe:DCGN) today announced that it has achieved a milestone under its... read more deCODE Study Identifying the First Gene Ever Linked to Common Forms of Stroke Published in Nature Genetics by deCODE genetics | Sep 23, 2003 | NEWS September 23, 2003 deCODE has identified both at-risk and pretective haplotypes within the PDE4D gene, and is applying its findings to develop novel drugs and diagnostics deCODE’s landmark study in the genetics of stroke, identifying the first gene ever linked to... read more deCODE’s RoboHTC™ System to Support AstraZeneca’s Structure-based Drug Design Capabilities by deCODE genetics | Apr 8, 2003 | NEWS RoboHTC is an integrated hardware and informatics solution for designing, generating, imaging, storing and annotating protein crystallization experiments Reykjavik, ICELAND, April 8, 2003 — deCODE genetics (Nasdaq/Nasdaq Europe:DCGN) today announced that AstraZeneca... read more deCODE and Families of Spinal Muscular Atrophy Launch Landmark Effort to Develop Effective Treatment for SMA by deCODE genetics | Feb 12, 2003 | NEWS deCODE enlisted to carry out the latest stage in one of the most aggressive drug development drives ever undertaken by a family-based patients’ organization Reykjavik, ICELAND, and Libertyville, ILLINOIS, February 12, 2003 — deCODE genetics (Nasdaq/Nasdaq Europe:DCGN)... read more deCODE Locates First Gene Ever Linked to Psoriatic Arthritis by deCODE genetics | Dec 13, 2002 | NEWS Reykjavik, ICELAND, December 13, 2002 — deCODE genetics (Nasdaq/Nasdaq Europe:DCGN) announced today that team of deCODE scientists has mapped to a small segment of chromosome 16 a gene contributing to psoriatic arthritis. This represents the first genetic factor... read more deCODE Replicates Schizophrenia Findings in Second Population by deCODE genetics | Dec 13, 2002 | NEWS Reykjavik, ICELAND, December 13, 2002 — deCODE genetics (Nasdaq/Nasdaq Europe:DCGN) announced today that a large association study carried out by its scientists and colleagues in Scotland has confirmed the significant link between the Neuregulin 1 gene and... read more deCODE and Wyeth in Pharmacogenomics Collaboration by deCODE genetics | Nov 20, 2002 | NEWS deCODE will apply its expertise in in vitro pharmacogenomics to provide gene expression data in relation to a Wyeth candidate treatment for respiratory disease Reykjavik, ICELAND, November 20, 2002 — deCODE genetics (Nasdaq/Nasdaq Europe:DCGN) today announced the... read more deCODE Generates First X-ray based, 3-D Image of How Important Anti-cancer Drug Works by deCODE genetics | Nov 11, 2002 | NEWS Highlights deCODE’s capabilities in structural biology and x-ray protein crystallography; may enable design of more effective anti-cancer compounds Reykjavik, ICELAND, November 11, 2002 — deCODE genetics (Nasdaq/Nasdaq Europe:DCGN) today announced that scientists from... read more deCODE and Merck Form Landmark Alliance in Obesity by deCODE genetics | Sep 27, 2002 | NEWS Alliance brings together world-leading capabilities in genetics and drug development to speed the discovery of new treatments Reykjavik, ICELAND, September 27, 2002 — deCODE genetics (Nasdaq/Nasdaq Europe:DCGN) and Merck & Co., Inc. (NYSE:MRK) today announced the... read more deCODE Publishes Landmark Study Linking the Neuregulin 1 Gene to Schizophrenia by deCODE genetics | Jul 24, 2002 | NEWS Research yields promising drug targets impacting underlying biology of the disease; Findings form the basis of deCODE’s most advanced drug discovery program Reykjavik, ICELAND, July 24, 2002 — deCODE genetics (Nasdaq/Nasdaq Europe:DCGN) today announced the publication... read more deCODE Announces Fundamental Discoveries in the Genetics and Pharmacogenomics of Asthma and Allergy by deCODE genetics | Jul 17, 2002 | NEWS Discoveries will be used to develop novel diagnostic tools and therapies for asthma and allergies, and to optimize patient benefit from existing drugs Reykjavik, ICELAND, July 17, 2002 — deCODE genetics (Nasdaq/Nasdaq Europe:DCGN) today announced that its scientists... read more deCODE Announces Mapping of a Hypertension Gene on Chromosome 18 by deCODE genetics | Jun 26, 2002 | NEWS deCODE study published this month reveals the strongest genetic linkage ever found to the common form of the condition. Reykjavik, ICELAND, June 26, 2002 — deCODE genetics (Nasdaq/Nasdaq Europe:DCGN) today announced that a team of its scientists has located a gene... read more deCODE Publishes High-resolution Genetic Map of the Human Genome by deCODE genetics | Jun 9, 2002 | NEWS · Landmark study creates "user’s guide" to the human genome; will aid in finalizing the assembly of the genome and in applying genomics to create better medicine. · Leverages deCODE’s genealogical resources, genotyping capabilities and software; results and data made... read more Genetic link to endometriosis – unique Icelandic study provides further proof by deCODE genetics | Feb 28, 2002 | NEWS February 28, 2002 A woman has more than five times the normal risk of developing endometriosis if her sister has the disease, according to research published today (Thursday 28 February) in Europe’s leading reproductive medicine journal, Human Reproduction*. Moreover,... read more deCODE and Roche Announce Mapping of Gene Linked to Rheumatoid Arthritis by deCODE genetics | Nov 29, 2001 | NEWS The discovery points the way to new predictive diagnostic markers and drug targets for RA Reykjavik, ICELAND and Basel, SWITZERLAND, November 29, 2001 — deCODE genetics (Nasdaq/Nasdaq Europe:DCGN) and Roche today announced that deCODE scientists have mapped the first... read more deCODE Locates First Gene Linked to Late-onset Parkinson’s Disease by deCODE genetics | Oct 23, 2001 | NEWS Reykjavik, ICELAND, October 23, 2001 ¾ Scientists at deCODE genetics (Nasdaq/Nasdaq Europe:DCGN) have successfully mapped a gene contributing to late-onset Parkinson’s disease, the first genetic factor ever mapped for the most common form of the disease. The company... read more deCODE and Roche Announce the Location of Genes Linked to Obesity and Anxiety by deCODE genetics | Sep 11, 2001 | NEWS Reykjavik, ICELAND and Basel, SWITZERLAND, September 11, 2001 — deCODE genetics (Nasdaq/Nasdaq Europe: DCGN) and Roche today announced that deCODE scientists have mapped genes contributing to two of the biggest public health challenges in the developed world: obesity... read more deCODE and Roche Announce Identification of Stroke Gene and Location of Gene Linked to Type 2 Diabetes by deCODE genetics | May 22, 2001 | NEWS Reykjavik, ICELAND and Basel, SWITZERLAND, May 22, 2001 — deCODE genetics (Nasdaq/Nasdaq Europe:DCGN) and Roche today announced two new accomplishments in their research alliance to characterize the genetic factors contributing to important common diseases. deCODE... read more The majority of Icelandic female settlers came from the British Isles by deCODE genetics | Feb 2, 2001 | NEWS Results of reasearch on the origin of the settlers of the North Atlantic islands Reykjavik 2. february, 2001 – For the last three years, deCODE genetics and Oxford University have been collaborating on one of the biggest research projects ever on the origins of a... read more deCODE genetics and Roche Announce Identification of Schizophrenia Gene by deCODE genetics | Oct 20, 2000 | NEWS Reykjavik, ICELAND, and Basel, SWITZERLAND, October 20, 2000 – deCODE genetics (Nasdaq/Easdaq: DCGN) and Roche announced today that scientists at deCODE together with psychiatrists from the Icelandic healthcare system have identified a gene linked to schizophrenia.... read more deCODE genetics and Roche Announce Milestone in Alzheimer’s Research by deCODE genetics | Aug 18, 2000 | NEWS Reykjavik, ICELAND, and Basel, SWITZERLAND, August 18, 2000 — deCODE genetics (Nasdaq/Easdaq: DCGN) and F.Hoffmann-La Roche announced today that scientists at deCODE have successfully mapped a novel gene that contributes to the occurrence of the common form of... read more Roche Announces Mapping of Stroke Gene by deCODE genetics | Mar 29, 2000 | NEWS March 29, 2000 Roche announced today that scientists at deCODE genetics, based in Reykjavik, Iceland, have reached an important milestone in their collaborative research on the genetics of common forms of stroke by successfully mapping a gene that contributes to the... read more deCODE GENETICS OF ICELAND MAPS A GENE LINKED TO PRE-ECLAMPSIA by deCODE genetics | Sep 19, 1999 | NEWS Reykjavik, September 19th, 1999 — deCODE genetics, Inc. announced today that they have identified a locus on chromosome 2p13 that contains a gene that is linked to pre-eclampsia in women — a condition that is indicated in an estimated three to seven percent of... read more Decode Genetics and Roche Announce Progress in Osteoarthritis Research Program by deCODE genetics | Mar 26, 1999 | NEWS Reykjavik, Iceland, March 26, 1999 — deCODE genetics and Roche announced today that scientists at deCODE have successfully mapped a gene linked to osteoarthritis to an area on a human chromosome. This finding will focus further efforts aimed at identifying this gene... read more Icelandic Genomics Company Identifies Location of Gene for Essential Tremor by deCODE genetics | Aug 25, 1997 | NEWS Reykjavik, ICELAND, August 25, 1997 — deCODE genetics today announced the publication of a scientific paper in the current issue of Nature Genetics (vol. 17) that describes the localization of a gene, FET1, responsible for familial essential tremor (FET) to human... read more ABOUT deCODE HOME COMPANY ABOUT deCODE MANAGEMENT POLICIES MEDIA RESOURCES SCIENCE PUBLICATIONS NEWS CAREERS CONTACT MANAGEMENT MANAGEMENT POLICIES CAREERS AVAILABLE POSITIONS CONTACT NEWS LATEST NEWS New study on inheritance and fetal growth New biomarker for osteoarthritis ADDRESS deCODE genetics Sturlugata 8 | 101 Reykjavik Iceland Phone +354 570 1900 deCODE genetics | Sturlugata 8 | 101 Reykjavik | Iceland | phone +354 570 1900 Þessi vefur notar fótspor (e. cookies) til að bæta upplifun þína á vefnum. Með því að smella á ,,Samþykkja valin fótspor“ samþykkir þú notkun á fótsporum til þess að auka virkni vefsins, greina vefnotkun og til að geta notað lausnir frá samfélagsmiðlum. RejectSettings Accept